iDNA Genomics Public (CYS:IDNA) Debt-to-EBITDA : 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CYS:IDNA iDNA Genomics Public Ltd CYS:IDNA
23 GF Score
Price €16.40
! 2 Warning Signs
View Full Analysis

What is iDNA Genomics Public Debt-to-EBITDA?

iDNA Genomics Public CYS:IDNA 23 Debt-to-EBITDA is 0.00 as of . 20. GuruFocus rates CYS:IDNA with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Debt-to-EBITDA measures a company's ability to pay off its debt.

iDNA Genomics Public's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was €0.00 Mil. iDNA Genomics Public's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was €0.00 Mil. iDNA Genomics Public's annualized EBITDA for the quarter that ended in . 20 was €0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for iDNA Genomics Public's Debt-to-EBITDA or its related term are showing as below:

CYS:IDNA's Debt-to-EBITDA is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.475
* Ranked among companies with meaningful Debt-to-EBITDA only.

iDNA Genomics Public  (CYS:IDNA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

iDNA Genomics Public Debt-to-EBITDA Related Terms

iDNA Genomics Public Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for iDNA Genomics Public's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iDNA Genomics Public Debt-to-EBITDA Chart

iDNA Genomics Public Annual Data
Trend
Debt-to-EBITDA

iDNA Genomics Public Semi-Annual Data
Debt-to-EBITDA

CYS:IDNA vs : Debt-to-EBITDA Comparison

For the Diagnostics & Research subindustry, iDNA Genomics Public's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iDNA Genomics Public Debt-to-EBITDA vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, iDNA Genomics Public's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where iDNA Genomics Public's Debt-to-EBITDA falls into.


CYS:IDNA
23GF Score
iDNA Genomics Public Ltd CYS:IDNA
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iDNA Genomics Public Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

iDNA Genomics Public's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / N/A
=N/A

iDNA Genomics Public's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (. 20) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of 0.00 mean?
iDNA Genomics Public (CYS:IDNA) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on iDNA Genomics Public.
Is iDNA Genomics Public's Debt-to-EBITDA too high?
iDNA Genomics Public's current Debt-to-EBITDA is 0.00. Overall, iDNA Genomics Public has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does iDNA Genomics Public's Debt-to-EBITDA compare to ?
iDNA Genomics Public's Debt-to-EBITDA of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Debt-to-EBITDA is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.48, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on iDNA Genomics Public. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iDNA Genomics Public's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iDNA Genomics Public stock overvalued right now?
iDNA Genomics Public (CYS:IDNA) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. iDNA Genomics Public's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For iDNA Genomics Public (CYS:IDNA), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

iDNA Genomics Public Business Description

Comparable Companies
Address 7 Hatzidaki Street, Trypiotis, Nicosia, CYP, 1066
iDNA Genomics Public Ltd operates in the field of genomics and biotechnology and specializes in personalized health care. Its purpose is to develop and provide genetic tests in the field of genomics, through professionals (Medical Genomics) and directly to the consumer (Direct-to-Consumer Genomics).
23GF Score

Get the complete analysis for CYS:IDNA

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.40
Price